# APBA Kısa Özet

The U.S. Food and Drug Administration (FDA) has approved Mimrylo (rusfertide), a first-in-class subcutaneous therapy for adults with polycythemia vera, a rare blood disorder characterized by overproduction of red blood cells. This approval marks the first treatment that mimics hepcidin, a natural hormone that regulates iron availability and red blood cell production.

# Çalışma neyi araştırdı?

The FDA approval was based on data from the VERIFY trial (NCT03766097), a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of rusfertide in adults with polycythemia vera who required frequent phlebotomies despite standard therapy. The trial enrolled 293 patients across multiple centers and was designed to assess the proportion of patients who did not meet criteria for phlebotomy between weeks 20 and 32 of the study.

# Yöntem

The VERIFY trial randomized patients in a 1:1 ratio to receive either rusfertide (subcutaneous injection) or placebo once weekly. Treatment initiation began at a dose of 19 mg, with titration allowed to maintain hematocrit levels below 45%. The primary endpoint was the proportion of patients who did not require phlebotomy between weeks 20 and 32. Secondary endpoints and safety assessments included monitoring of serious adverse events, treatment-emergent events, and hematocrit levels throughout the 32-week double-blind period.

# Temel bulgular

In the VERIFY trial, the efficacy results were striking. Among patients treated with Mimrylo (rusfertide), 76.9% required no phlebotomy between weeks 20 and 32, compared to only 6.7% of those on placebo. This represents a statistically significant improvement in the primary endpoint. Regarding safety, serious adverse events were reported in 5.5% of Mimrylo-treated patients. The most common treatment-related adverse events included injection site reactions and transient increases in liver enzymes. Hematocrit levels were successfully maintained below the target threshold of 45% in the majority of rusfertide-treated patients.

# Bulgular ne anlama geliyor?

These findings demonstrate that Mimrylo offers a disease-modifying approach for polycythemia vera by mimicking hepcidin to limit iron availability, thereby reducing the overproduction of red blood cells. For patients who require frequent phlebotomies to manage their hematocrit, this therapy provides a potential alternative that can reduce the need for invasive bloodletting procedures. The ability to maintain hematocrit below 45% without frequent phlebotomies represents a significant advancement in the management of this rare blood disorder. However, the 32-week study duration limits the ability to assess long-term safety and durability of response beyond the trial period.

# Klinik önem

From a clinical perspective, the approval of Mimrylo expands the treatment arsenal for polycythemia vera, particularly for patients who are phlebotomy-dependent despite standard therapy. The subcutaneous administration once weekly offers a convenient dosing schedule. The reduction in phlebotomy frequency can improve patient quality of life and reduce the logistical burden on healthcare systems. Clinicians should note that treatment must be initiated and monitored by healthcare professionals experienced in managing polycythemia vera. As with any new therapy, the benefit-risk profile should be individualized for each patient, considering factors such as comorbidities and concomitant medications.

# Sınırlılıklar

Several limitations of the VERIFY trial and the current evidence base should be acknowledged. The study population was limited to adults with polycythemia vera who required frequent phlebotomies despite standard therapy, meaning results may not fully generalize to all polycythemia vera patients. The 32-week study duration limits long-term safety assessment and the understanding of sustained efficacy beyond six months. The placebo-controlled design does not reflect real-world sequential therapy use, where patients may transition between different treatments. Additionally, specific adverse event rates beyond serious AEs were not fully detailed in the press announcement, and an open-label extension phase was not described. These factors underscore the need for continued post-marketing surveillance and real-world evidence generation.